Because of marked inter-subject variability in interferon pharmacokinetics, it is recommended that patients with severe renal impairment be closely monitored during treatment with PegIntron (see section 4.2)
Kuna interferooni farmakokineetika omab märkimisväärset individuaalset variaablust, on soovitatav, et PegIntron’ i ravil olevaid raske neerukahjustusega patsiente jälgitaks ravi käigus hoolikalt (vt lõik 4. 2).